We read with great interest, "When the Heart Runs Out of Heartbeats: Treatment Options for Refractory End-Stage Heart Failure," by Ahmad et al, 1 which describes the successful bridging of a patient with heart failure and cardiogenic shock to heart transplantation. This case highlights the potency of therapy in the era of mechanical circulatory support and raises the issue of how long to wait before implementing long-term mechanical circulatory support. Specifically, the patient described by Ahmad et al progressed from ambulatory to cardiogenic shock supported for 3 weeks on an intra-aortic balloon pump before implantation of a left ventricular assist device. Although definitive data are lacking, our bias is toward early implantation of definitive mechanical circulatory support in such a patient.
To the Editor:
We read with great interest, "When the Heart Runs Out of Heartbeats: Treatment Options for Refractory End-Stage Heart Failure," by Ahmad et al, 1 which describes the successful bridging of a patient with heart failure and cardiogenic shock to heart transplantation. This case highlights the potency of therapy in the era of mechanical circulatory support and raises the issue of how long to wait before implementing long-term mechanical circulatory support. Specifically, the patient described by Ahmad et al progressed from ambulatory to cardiogenic shock supported for 3 weeks on an intra-aortic balloon pump before implantation of a left ventricular assist device. Although definitive data are lacking, our bias is toward early implantation of definitive mechanical circulatory support in such a patient.
In 2005, The Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) was established to track outcomes in patients who were treated with a mechanical circulatory support device for heart failure. As part of INTERMACS, 7 clinical profiles were defined based on the time course and acuity of decompensation. 2 For INTERMACS 3 patients (stable but inotrope-dependent) who are heart transplant candidates, timing of left ventricular assist device implantation is based on anticipated wait time. For larger patients with blood type O, the United Network for Organ Sharing (UNOS) 1B expected wait time in most allocation zones is approximately 1 year. Importantly, the expected 1-year mortality for INTERMACS 3 approaches 60% to 80%. 3, 4 Because 1-year survival with continuousflow left ventricular assist devices used for bridge to transplantation is 85%, 5 and quality-of-life benefits are seen within 3 months, we believe it is imperative to consider early left ventricular assist device implementation.
When a heart transplant candidate progresses to INTERMACS 1 (cardiogenic shock), the clock starts ticking for heart replacement therapy. The in-hospital mortality for cardiogenic shock is >50%. Temporary mechanical circulatory support with an intra-aortic balloon pump is appropriate for initial stabilization. Failure to achieve stabilization within hours indicates a higher level of mechanical circulatory support is required. In patients who are stabilized with an intra-aortic balloon pump, a wean may be attempted after optimization of hemodynamics. Failure to wean indicates dependency on heart replacement therapy. In a UNOS 1A patient with a short expected wait time, intra-aortic balloon pump plus inotropes can be used as a bridge to transplantation. In contrast, in patients with a long expected wait time, transition to long-term support is required. Unless there are mitigating circumstances, once an intra-aortic balloon pump is placed for cardiogenic shock in a heart transplant candidate, the decision to proceed to left ventricular assist device should be made expeditiously. Maintenance on an intra-aortic balloon pump is associated with bleeding, limb ischemia, thromboembolic events, and infection.
The left ventricular assist device is a vital tool to optimize survival and quality of life in advanced heart failure. Although data are lacking to guide optimal timing of left ventricular assist device implantation, we believe that early implementation of definitive mechanical circulatory support is essential to achieving the best outcomes for bridge-to-transplantation left ventricular assist device candidates.
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